Azathioprine (2.0 to 4.7 mg/kg/day) was administered to 15 multiple sclerosis patients for an average of 15 months. The conditions of five of six patients who had chronic progressive courses prior to administration of azathioprine continued to deteriorate. Four of six patients who had a remitting and exacerbating course had six exacerbations in a total of 78 months of treatment, an average of one exacerbation per 13 months. Evidence of varying degrees of immune suppression occurred in approximately half the patients. Neither the type nor degree of suppression, nor the dose of azathioprine required to depress the patients' peripheral white blood cell count to 4,000/cu mm bore any relationship to their clinical course. We see no evidence for beneficial effect of azathioprine administered to multiple sclerosis patients in doses ordinarily regarded as immunosuppressive.
Silberberg D, Lisak R, Zweiman B. Multiple Sclerosis Unaffected by Azathioprine in Pilot Study. Arch Neurol. 1973;28(3):210–212. doi:10.1001/archneur.1973.00490210090017
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: